Aromatase inhibitors in breast cancer. [N Engl J Med. 2003] - PubMed

loading

Review [Aromatase inhibitors]. [Pol Arch Med Wewn. 2004]
Review [Aromatase inhibitors].
Krysiak R, Okopień B, Herman ZS. Pol Arch Med Wewn. 2004 Mar; 111(3):375-84.
Review The therapeutic potential of aromatase inhibitors. [Expert Opin Investig Drugs. 2003]
Review The therapeutic potential of aromatase inhibitors.
Miller WR, Jackson J. Expert Opin Investig Drugs. 2003 Mar; 12(3):337-51.
Review Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors. [Drugs. 2002]
Review Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors.
Goss PE, Strasser K. Drugs. 2002; 62(6):957-66.
Review Use of aromatase inhibitors in breast carcinoma. [Endocr Relat Cancer. 1999]
Review Use of aromatase inhibitors in breast carcinoma.
Santen RJ, Harvey HA. Endocr Relat Cancer. 1999 Mar; 6(1):75-92.
Review Aromatase inhibitors for breast cancer: pharmacoeconomic considerations. [Expert Opin Pharmacother. 2001]
Review Aromatase inhibitors for breast cancer: pharmacoeconomic considerations.
Higa GM. Expert Opin Pharmacother. 2001 Jun; 2(6):987-95.

Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial. [Oncol Rep. 2013]
Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial.
Nishimura R, Anan K, Yamamoto Y, Higaki K, Tanaka M, Shibuta K, Sagara Y, Ohno S, Tsuyuki S, Mase T, et al. Oncol Rep. 2013 May; 29(5):1707-13. Epub 2013 Feb 27.
Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients. [EPMA J. 2010]
Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients.
Mallmann MR, Staratschek-Jox A, Rudlowski C, Braun M, Gaarz A, Wolfgarten M, Kuhn W, Schultze JL. EPMA J. 2010 Sep; 1(3):421-37. Epub 2010 Aug 20.
Genotoxic effects of some l-[(benzofuran-2-yl)-phenylmethyl]-imidazoles on MCF-7 cell line. [Res Pharm Sci. 2012]
Genotoxic effects of some l-[(benzofuran-2-yl)-phenylmethyl]-imidazoles on MCF-7 cell line.
Etebari M, Khodarahmi GA, Jafarian-Dehkordi A, Nokhodian Z. Res Pharm Sci. 2012 Jul; 7(3):189-95.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Aromatase inhibitors in breast cancer.
Aromatase inhibitors in breast cancer.
N Engl J Med. 2003 Jun 12 ;348(24):2431-42.

PubMed
12802030[uid] (1)
PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed